CTKB - Cytek Biosciences Inc

CTKB - Cytek Biosciences Inc

https://cytekbio.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA - Cytek Biosciences ( NASDAQ:CTKB )

Benzinga • 4 days, 18 hours ago • score: 0.22

FREMONT, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc.

Cytek Biosciences, Inc. ( CTKB ) Beats Q2 Earnings Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.03

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire • 3 months, 2 weeks ago • score: 0.27

FREMONT, Calif., May 28, 2025 ( GLOBE NEWSWIRE ) -- Cytek Biosciences, Inc. ( Nasdaq: CTKB ) , a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL.

Cytek Biosciences, Inc. ( CTKB ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months ago • score: -0.03

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -125% and 5.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-09 (Snapshot)

None

52W High

$7.63

52W Low

$2.37

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.36

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

370.37

EV/EBITDA (<8 favorable)

-133.96

EV/Revenue (<3 favorable)

1.39

P/S (TTM) (<3 favorable)

2.61

P/B (<3 favorable)

1.36

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.24%

Institutions (25–75% balanced)

63.38%

Shares Outstanding

127,224,000

Float

108,731,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

196,035,000

Gross Profit (TTM)

106,681,000

EPS (TTM)

-0.05

Profit Margin (>10% good)

-0.03%

Operating Margin (TTM) (higher better)

-0.23%

ROE (TTM) (>15% strong)

-0.02%

EPS YoY (Quarterly) (>10% good)

0.74

Revenue YoY (Quarterly) (>8% good)

-0.02

Momentum

Bearish momentum

Value

0.0377

Previous

0.0480

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025